Year-end Sale % OFF 
Abstract
BackgroundE protein of tick-borne encephalitis virus (TBEV) and other flaviviruses is located on the surface of the viral particle. Domain III of this protein seems to be a promising component of subunit vaccines for prophylaxis of TBE and kits for diagnostics of TBEV.MethodsThree variants of recombinant TBEV E protein domain III of European, Siberian and Far Eastern subtypes fused with dextran-binding domain of Leuconostoc citreum KM20 were expressed in E. coli and purified. The native structure of domain III was confirmed by ELISA antibody kit and sera of patients with tick-borne encephalitis. Immunogenic and protective properties of the preparation comprising these recombinant proteins immobilized on a dextran carrier with CpG oligonucleotides as an adjuvant were investigated on the mice model.ResultsAll 3 variants of recombinant proteins immobilized on dextran demonstrate specific interaction with antibodies from the sera of TBE patients. Thus, constructed recombinant proteins seem to be promising for TBE diagnostics. The formulation comprising the 3 variants of recombinant antigens immobilized on dextran and CpG oligonucleotides, induces the production of neutralizing antibodies against TBEV of different subtypes and demonstrates partial protectivity against TBEV infection.ConclusionsStudied proteins interact with the sera of TBE patients, and, in combination with dextran and CPGs, demonstrate immunogenicity and limited protectivity on mice compared with reference “Tick-E-Vac” vaccine.Electronic supplementary materialThe online version of this article (doi:10.1186/s12879-016-1884-5) contains supplementary material, which is available to authorized users.
Highlights
E protein of tick-borne encephalitis virus (TBEV) and other flaviviruses is located on the surface of the viral particle
We found that all 3 variants of TBEV E protein domain III immobilized on dextran can interact with the sera of patients with Tick-borne encephalitis (TBE)
Preparation comprising the recombinant TBEV E protein domain III and CpG oligonucleotides induces the production of neutralizing antibodies, but demonstrates limited protectivity as compared with Tick-E-Vac vaccine
Summary
E protein of tick-borne encephalitis virus (TBEV) and other flaviviruses is located on the surface of the viral particle. Domain III of this protein seems to be a promising component of subunit vaccines for prophylaxis of TBE and kits for diagnostics of TBEV. Tick-borne encephalitis (TBE) presents a threat for a public health in different countries [1]. European TBE vaccines are prepared from European TBEV strains, and Russian – from Far-Eastern ones. Technological process of inactivated vaccine preparation includes accommodation of large amounts of highly neurovirulent virus stock, which complicates the vaccine production site and elaborates biosafety and biosecurity measures. There is a need in development of new low cost subunit vaccines with a safe production process that could cause prolonged immunity without additional revaccinations
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
